title: Targeted therapies: detrimental treatment for nonsmall cell lung cancer without driver mutations.
authors.affiliation: Dept of Intensive Care and Oncological Emergencies and Thoracic Oncology, Institut Jules Bordet, Centre des tumeurs de l'université Libre de Bruxelles, Brussels, Belgium thierry.berghmans@bordet.be.
authors.forename: Thierry
authors.initials: T
authors.lastname: Berghmans
authors.affiliation: Dept of Intensive Care and Oncological Emergencies and Thoracic Oncology, Institut Jules Bordet, Centre des tumeurs de l'université Libre de Bruxelles, Brussels, Belgium.
authors.forename: Anne-Pascale
authors.initials: AP
authors.lastname: Meert
authors.affiliation: Dept of Pneumology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Quoix
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage*; D003841:Deoxycytidine / Q000031:analogs & derivatives*; D000069347:Erlotinib Hydrochloride / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male
chemical_list: D003841:Deoxycytidine; D000068258:Bevacizumab; D000069347:Erlotinib Hydrochloride; D002945:Cisplatin